Paradigm and TD2 Announce Strategic Partnership For Tumor Profiling Service
Collaboration to provide expanded use of Paradigm Cancer Diagnostic (PCDx™) service by oncologists across large oncology network
SCOTTSDALE, AZ and ANN ARBOR, MI Monday, April 20, 2015 -- Paradigm and Translational Drug Development (TD2) today announced a partnership under which Paradigm will provide their PCDx test to TD2’s affiliated oncology provider networks.
PCDx is a Next-Generation Sequencing (NGS) based diagnostic test that is designed to provide physicians and patients with a more targeted, personalized approach to cancer treatment by identifying the underlying genomic and proteomic alterations of a patients tumor’s DNA, RNA & Protein. The service is unique as the only commercially available NGS-based assay that interrogates DNA mutations, copy number variations, gene fusions and messenger RNA expression (mRNA) in typically less than five business days.
This collaboration with Paradigm will provide oncologists in the TD2 networks access to this cutting edge technology and make possible more informed and individually tailored treatment strategies for patients.
“Molecular profiling of patient tumors is a critical component of patient care that assists patients and their doctors in the selection of treatment choices more likely to provide clinical benefit,” said TD2’s CEO Stephen Gately, PhD.” It is important for TD2 precision oncology services to identify a key strategic partner to augment our clinical services. “Access to the highest quality testing within clinically relevant timelines is essential for patients in our networks” said Gately, “but more importantly the PCDx test provides druggable targets and treatment options for those who need it the most.”
“PCDx is one of the most comprehensive, yet targeted, clinical-grade NGS-based test on the market today,” said Paradigm’s CEO Robert Penny, MD, PhD. “Our team’s ability to interrogate the most relevant genomic targets at over 5,000x average depth of coverage with 66 therapeutic associations in 4-5 business days ensures the highest degree of quality and clinical relevance for patients and physician colleagues. We look forward to this relationship with TD2 helping benefit thousands of cancer patients annually.”
# # #
Paradigm is a molecular information corporation established to bring cutting-edge diagnostics to cancer patients and clinical trials by providing information about the genomic makeup of the patient’s cancer and potential therapies based on the specific characterization of the patient’s tumor that can impact the patient’s course of treatment. Paradigm’s Next-Generation Sequencing based diagnostic test PCDx provides oncologists and patients with more precise information about the specific cancer pathways in the patient and associations between the pathways and the specific drugs available that can affect the cancer to allow for more effective decision-making. The test is driven by supporting data and literature and provides more choices for patient care than currently available on the market. For more information visit http://www.paradigmdx.org.
Translational Drug Development (TD2) is an oncology development organization that provides innovative services for oncology-focused biopharmaceutical companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2's suite of capabilities provides for the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information on TD2 visit http://www.td2inc.com. TD2 is a portfolio company of ORIX Healthcare Capital.
About ORIX Healthcare Capital
ORIX Healthcare Capital provides financial and intellectual capital to companies in the healthcare space. Typical investments range from $20 million to $50 million, with the capacity to grow. ORIX Healthcare Capital is a business unit of ORIX USA, a Dallas-based financial services firm known for providing innovative capital solutions that clients need to propel their business to the next level. With more than 1,400 employees spanning seven primary offices across the U.S. and Brazil, ORIX USA and its family of companies hold $7 billion of assets and manage an additional $30 billion, approximately. Our parent company, ORIX Corporation, is a Tokyo-based, publicly owned international financial services company with operations in 36 countries and regions worldwide. ORIX Corporation is listed on the Tokyo (8591) and New York Stock Exchanges (IX). For more information on ORIX Healthcare Capital, visit www.orix.com.